- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03942042
A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
A Multicenter, Open-Label, Post Marketing Clinical Trial to Evaluate the Efficacy And Safety Of Ixekizumab in Patients With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Osaka, Japan, 545-8586
- Osaka City University Medical School Hospital
-
-
Aichi
-
Nagoya, Aichi, Japan, 467-8602
- Nagoya City University Hospital
-
-
Miyagi
-
Sendai-shi, Miyagi, Japan, 980-8574
- Tohoku University Hospital
-
-
Osaka
-
Hirakata, Osaka, Japan, 573-1191
- Kansai Medical University Hospital
-
-
Tokyo
-
Itabashi-ku, Tokyo, Japan, 173 8606
- Teikyo University Hospital
-
Minato-Ku, Tokyo, Japan, 105-8471
- Jikei University School of Medicine
-
Shinjuku-ku, Tokyo, Japan, 160-0023
- Tokyo Medical University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Present with GPP or EP based on an investigator-confirmed diagnosis and meet the associated criteria
- GPP: Meet the criteria for GPP set by Ministry of Health, Labour and Welfare (MHLW) at screening and baseline regardless of IL-36 mutation status.
- EP: Diagnosed to have BSA ≥80% involvement (with inflammatory erythema) at screening and baseline.
- Candidates for phototherapy and/or systemic therapy
- Men must agree to use a reliable method of birth control during the study
- Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment
Exclusion Criteria:
- History of drug-induced psoriasis
- Concurrent or recent use of any biologic agent
- Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study
- Have previously received ixekizumab
- Serious disorder or illness other than psoriasis
- Serious infection within the last 12 weeks
- Breastfeeding or nursing (lactating) women
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ixekizumab
Induction Dosing Period: Participants received 160 milligrams (mg) ixekizumab subcutaneously (SC) as 2 injections at Week 0 followed by 80 mg ixekizumab SC as 1 injection at Week 2, 4, 6, 8 and 10. Maintenance Dosing Period: Participants with Global Improvement Score (GIS) = 1 at Week 12 are responders who will complete the study. Participants who are inadequate responders (GIS ≥2 at Week 12 and based on the investigators' discretion) will be administered 80 mg ixekizumab SC as 1 injection at Week 12, 14, 16, and 18 or until they achieve a GIS score of 1. |
Administered SC
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maintenance Dosing Period: Number of Participants Who Improved Global Improvement Score (GIS) at Least 1 Point From Week 12 Through Week 20 and With ≤2 of GIS
Time Frame: Week 12 through Week 20
|
GIS was assessed in the 4 grades by comparing the psoriatic findings: (1) resolved, (2) improved, (3) unchanged, or (4) worsened.
The global improvement score was assessed based on the comparison of the psoriatic findings, Static Physician Global Assessment (sPGA), Psoriasis Area and Severity Index (PASI) score, and other evaluations with those at the baseline.
|
Week 12 through Week 20
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maintenance Dosing Period: Number of Participants With GIS Grade 1: Resolved
Time Frame: Week 20
|
GIS was assessed in the 4 grades by comparing the psoriatic findings: (1) resolved, (2) improved, (3) unchanged, or (4) worsened.
The global improvement score was assessed based on the comparison of the psoriatic findings, Static Physician Global Assessment (sPGA), Psoriasis Area and Severity Index (PASI) score, and other evaluations with those at the baseline.
|
Week 20
|
Maintenance Dosing Period: Number of Participants With GIS Grade 2: Improved
Time Frame: Week 20
|
GIS was assessed in the 4 grades by comparing the psoriatic findings: (1) resolved, (2) improved, (3) unchanged, or (4) worsened.
The global improvement score was assessed based on the comparison of the psoriatic findings, Static Physician Global Assessment (sPGA), Psoriasis Area and Severity Index (PASI) score, and other evaluations with those at the baseline.
|
Week 20
|
Maintenance Dosing Period: Number of Participants With GIS Grade 3: Unchanged
Time Frame: Week 20
|
GIS was assessed in the 4 grades by comparing the psoriatic findings: (1) resolved, (2) improved, (3) unchanged, or (4) worsened.
The global improvement score was assessed based on the comparison of the psoriatic findings, Static Physician Global Assessment (sPGA), Psoriasis Area and Severity Index (PASI) score, and other evaluations with those at the baseline.
|
Week 20
|
Maintenance Dosing Period: Number of Participants With GIS Grade 4: Worsened
Time Frame: Week 20
|
GIS was assessed in the 4 grades by comparing the psoriatic findings: (1) resolved, (2) improved, (3) unchanged, or (4) worsened.
The global improvement score was assessed based on the comparison of the psoriatic findings, Static Physician Global Assessment (sPGA), Psoriasis Area and Severity Index (PASI) score, and other evaluations with those at the baseline.
|
Week 20
|
Maintenance Dosing Period: Number of Participants Who Achieved Static Physician Global Assessment (sPGA) of (0, 1)
Time Frame: Week 20
|
The sPGA is a physician's determination of the participant's psoriasis lesions overall at a given time point categorized by descriptions for induration, erythema, and scaling.
For the analysis of responses, the participant's psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), or very severe (5).
An sPGA assessed as either 0 or 1 represents a clinically meaningful response of minimal plaque severity or complete resolution of psoriasis.
|
Week 20
|
Maintenance Dosing Period: Number of Participants Who Achieved at Least a 75% Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score (PASI 75) Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score (PASI 75)
Time Frame: Week 20
|
PASI combines assessments of the extent of body surface involvement in 4 regions (head & neck(h), trunk(t), arms(u), legs(l)) & severity of scaling (S), redness (R), & plaque induration/infiltration (thickness, T) in each region. Severity is rated for each index (R, S, T) on a 0-4 scale (0 for no involvement up to 4 for severe involvement): 0 = none, 1 = slight, 2 = mild, 3 = moderate, 4 = severe Fraction of total body surface area (BSA) affected is graded on a 0-6 scale (0 for no involvement to 6 for 90% - 100% involvement): 0 = 0% (clear), 1 = >0% to <10%, 2 = 10% to <30%, 3 = 30% to <50%, 4 = 50% to <70%, 5 = 70% to 90%, 6 = 90% to 100%. Overall score ranges from 0 (no psoriasis) to 72 (most severe disease). |
Week 20
|
Maintenance Dosing Period: Change From Baseline in Psoriasis Scalp Severity Index (PSSI) in Participants With Scalp Involvement at Baseline
Time Frame: Baseline, Week 20
|
The scalp was assessed for erythema (redness), induration (hardness), and desquamation (shedding of skin) and percentage of area affected as follows: Erythema, Induration and Desquamation: 0 = Absent
Percent of Scalp Involved:
The PSSI score is a composite score derived from the sum of the scores for erythema, induration and desquamation multiplied by the score for the extent of scalp area involved (percent of scalp involved). The range is 0 (no psoriasis) to 72 (Most severe Disease). |
Baseline, Week 20
|
Maintenance Dosing Period: Change From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis Body Surface Area (BSA) Involvement of Psoriasis
Time Frame: Baseline, Week 20
|
Percentage involvement of psoriasis on each participants body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand (including palm, fingers and thumb).
|
Baseline, Week 20
|
Maintenance Dosing Period: Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score
Time Frame: Baseline, Week 20
|
The DLQI is a simple, patient-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment.
Response categories include "not at all", "a little","a lot", and "very much", with corresponding scores of 0, 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0."
Totals range from 0 to 30 (the higher the score, the more quality of life is impaired) and a 5-point change from baseline is considered clinically relevant (Basra et al. 2008).
|
Baseline, Week 20
|
Maintenance Dosing Period: Number of Participants Who Developed Treatment-Emergent Anti-Ixekizumab Antibodies (TE-ADA)
Time Frame: Week 20
|
Number of participants who developed treatment-emergent anti-ixekizumab antibodies (TE-ADA) was summarized by treatment group.
|
Week 20
|
Maintenance Dosing Period: Number of Participants Who Developed Neutralizing Anti-Ixekizumab Antibody (NAb)
Time Frame: Week 20
|
Number of participants who developed neutralizing Anti-Ixekizumab antibody (NAb) was summarized by treatment group.
|
Week 20
|
Generalized Pustular Psoriasis (GPP) Only: Change From Baseline on Generalized Pustular Psoriasis Severity Index
Time Frame: Baseline, Week 20
|
GPP Severity Index was evaluated only for participants with pustular psoriasis at screening and at baseline.
This is a composite score derived from the sum of scores for assessment of dermal symptoms, systemic symptoms, and laboratory findings (range, 0 to 17, with 17 representing severe symptoms).
Skin symptoms were assessed by the score with the area of erythema (on a 0 to 3 scale), area of confluent pustules (on a 0 to 3 scale), and are of skin edema (on a 0 to 3 scale).
The total score will be assessed (range, 0 to 9, with 9 representing severe symptoms).
Systemic symptoms and laboratory findings were assessed by the score with fever (on a 0 to 2 scale), white blood cell (on a 0 to -2 scale), C-reactive protein (on a 0 to 2 scale) and Albumin (on a 0 to 2 scale).
The total score will be assessed (range, 0 to 8, with 8 representing severe symptoms).
|
Baseline, Week 20
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17154
- I1F-JE-RHCV (Other Identifier: Eli Lilly and Company)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Clinical Study Report (CSR)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Generalized Pustular Psoriasis
-
UCB Biopharma S.P.R.L.CompletedModerate to Severe Psoriasis | Generalized Pustular Psoriasis and Erythrodermic PsoriasisJapan
-
Shanghai Huaota Biopharmaceutical Co., Ltd.RecruitingGeneralized Pustular Psoriasis (GPP)China
-
AbbVieCompletedGeneralized Pustular Psoriasis (GPP) | Adalimumab | Japanese
-
Boehringer IngelheimCompleted
-
Janssen Pharmaceutical K.K.RecruitingGeneralized Pustular Psoriasis | Erythrodermic PsoriasisJapan
-
CorEvitasRecruitingGeneralized Pustular PsoriasisUnited States
-
Boehringer IngelheimCompletedGeneralized Pustular PsoriasisSpain, Taiwan, Thailand, Korea, Republic of, Germany, Malaysia, United States, Argentina, Belgium, Chile, China, France, Greece, Italy, Japan, Mexico, Netherlands, Philippines, Russian Federation, South Africa, Tunisia, Turkey, Vietnam
-
AnaptysBio, Inc.CompletedGeneralized Pustular PsoriasisUnited States, Australia, Georgia, Germany, Korea, Republic of, Malaysia, Morocco, Poland, Romania, Spain, Taiwan, Thailand, Tunisia, Turkey, Slovakia
-
Boehringer IngelheimCompletedPsoriasisTaiwan, Malaysia, France, Japan, Korea, Republic of, Tunisia
-
Janssen Pharmaceutical K.K.Completed
Clinical Trials on Ixekizumab
-
Shanghai Yueyang Integrated Medicine HospitalShanghai Skin Disease and Venereal Disease HospitalNot yet recruiting
-
Eli Lilly and CompanyCompletedPlaque PsoriasisUnited States, Puerto Rico
-
University of New MexicoCompletedLichen Planus | Lichen Planopilaris | Lichen Planus ScalpUnited States
-
Massachusetts Eye Research and Surgery InstitutionEli Lilly and CompanyRecruitingUveitis, Anterior | Panuveitis | Uveitis, Posterior | Uveitis, IntermediateUnited States
-
Eli Lilly and CompanyCompleted
-
Eli Lilly and CompanyCompletedPsoriatic ArthritisUnited States, France, Taiwan, Spain, Australia, Germany, United Kingdom, Poland, Czechia, Italy
-
Eli Lilly and CompanyCompletedRheumatoid ArthritisGermany, United States, Romania, Russian Federation, Argentina, Peru, Poland, Taiwan, Korea, Republic of, India, Chile
-
Eli Lilly and CompanyCompletedPsoriasisItaly, United States, Australia, Germany, Canada, Denmark, Japan, Poland, Hungary, Romania, United Kingdom
-
Second Affiliated Hospital, School of Medicine,...Not yet recruiting